Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Biochem Biophys Res Commun ; 420(4): 743-9, 2012 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-22465012

RESUMO

Bone marrow cell (BMC)-derived myofibroblast-like cells have been reported in various organs, including the pancreas. However, the contribution of these cells to pancreatic fibrosis has not been fully discussed. The present study examined the possible involvement of pancreatic stellate cells (PSCs) originating from BMCs in the development of pancreatic fibrosis in a clinically relevant rat model of acute pancreatitis induced by a choline-deficient/ethionine-supplemented (CDE) diet. BMCs from female transgenic mice ubiquitously expressing green fluorescent protein (GFP) were transplanted into lethally irradiated male rats. Once chimerism was established, acute pancreatitis was induced by a CDE diet. Chronological changes in the number of PSCs originating from the donor BMCs were examined using double immunofluorescence for GFP and markers for PSCs, such as desmin and alpha smooth muscle actin (αSMA), 1, 3 and 8 weeks after the initiation of CDE feeding. We also used immunohistochemical staining to evaluate whether the PSCs from the BMCs produce growth factors, such as platelet-derived growth factor (PDGF) and transforming growth factor (TGF) ß1. The percentage of BMC-derived activated PSCs increased significantly, peaking after 1 week of CDE treatment (accounting for 23.3±0.9% of the total population of activated PSCs) and then decreasing. These cells produced both PDGF and TGFß1 during the early stage of pancreatic fibrosis. Our results suggest that PSCs originating from BMCs contribute mainly to the early stage of pancreatic injury, at least in part, by producing growth factors in a rat CDE diet-induced pancreatitis model.


Assuntos
Células da Medula Óssea/patologia , Pâncreas/patologia , Células Estreladas do Pâncreas/patologia , Pancreatite/patologia , Animais , Quimerismo , Deficiência de Colina/complicações , Suplementos Nutricionais/efeitos adversos , Modelos Animais de Doenças , Etionina/administração & dosagem , Etionina/efeitos adversos , Fibrose , Proteínas de Fluorescência Verde/biossíntese , Masculino , Células Estreladas do Pâncreas/metabolismo , Pancreatite/etiologia , Fator de Crescimento Derivado de Plaquetas/biossíntese , Ratos , Ratos Endogâmicos Lew , Fator de Crescimento Transformador beta/biossíntese
2.
Exp Anim ; 59(4): 421-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20660988

RESUMO

Although chronic pancreatitis is a risk factor for pancreatic ductal adenocarcinoma (PDA), the relationship between chronic pancreatitis and PDA remains obscure. A critical obstacle to understanding the role of chronic pancreatitis is the lack of animal models. To develop one such model, mice were fed long-term with a choline deficient ethionine-supplemented (CDE) diet. Histological evaluation revealed that chronic pancreatitis, characterized by acinar atrophy, fibrosis and well-developed tubular complexes (TCs), was observed after 24 weeks of CDE diet treatment. Furthermore, expression of epidermal growth factor receptor (EGFR) and its ligands; serine protease inhibitor Kazal type 3 (Spink3) and transforming growth factor alpha (TGF alpha) and activation of K-Ras (GTP-Ras formation), which are frequently observed in human PDA, were indeed observed in parallel with TCs formation. Neoplastic lesions were not found after 54 weeks of treatment, suggesting that a continuation of CDE diet or another insult is required for the development of PDA.


Assuntos
Ração Animal/efeitos adversos , Deficiência de Colina/complicações , Etionina/efeitos adversos , Pancreatite Crônica/etiologia , Amilases/sangue , Animais , Biomarcadores/metabolismo , Western Blotting , Deficiência de Colina/patologia , Modelos Animais de Doenças , Receptores ErbB/metabolismo , Etionina/administração & dosagem , Feminino , Glicoproteínas/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Pâncreas/efeitos dos fármacos , Pâncreas/metabolismo , Pâncreas/patologia , Pancreatite Crônica/patologia , Proteínas Secretadas pela Próstata/metabolismo , Fator de Crescimento Transformador alfa/metabolismo , Inibidor da Tripsina Pancreática de Kazal , Proteínas ras/metabolismo
3.
Liver Int ; 29(4): 575-84, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19323784

RESUMO

BACKGROUND: Hepatic oval cells, progenitor cells in the liver, can differentiate into hepatocytes and bile duct cells both in vitro and in vivo. Although hepatic stellate cells are another important cell component in the liver, less attention has been focused on the relationship between hepatic oval cells and hepatic stellate cells. METHODS: Hepatic oval cells were isolated from rats fed a choline-deficient diet supplemented with 0.1% ethionine for 6 weeks and characterized by electron microscopy, flow cytometry, reverse transcription polymerase chain reaction, Western blot and bi-direction differentiation. After treatment with transforming growth factor-beta1 (TGF-beta1), changes in cell viability, morphology, extracellular matrix (ECM) expression and immune phenotype were analysed in these cultured and adherent hepatic oval cells. RESULTS: The primary cultured hepatic oval cells were positive for the oval cell-specific markers OV-6, BD-1/BD-2 and M2PK as well as the hepatocyte markers albumin and alpha-foetoprotein. These hepatic oval cells differentiated bipotentially into hepatocytes or bile duct-like cells under appropriate conditions. It is noteworthy that these bipotential hepatic oval cells expressed ECM genes stably, including collagens, matrix metalloproteinases and tissue inhibitor of mellatoproteinase. Furthermore, except for growth inhibition and morphological changes in the hepatic oval cells after exposure to TGF-beta1, there was an increased expression of ECM genes, the onset expression of snail and loss expression of E-cadherin. During this process, TGF-beta1 treatment induced an upregulation of marker genes for hepatic stellate cells in hepatic oval cells, such as desmin and GFAP. CONCLUSION: Except for the expression of ECM, the cultured hepatic oval cells could induce an increased expression of hepatic stellate cell markers by TGF-beta1 through an epithelial-mesenchymal transition process, which might indicate the contribution of hepatic oval cells to liver fibrosis.


Assuntos
Proteínas da Matriz Extracelular/metabolismo , Expressão Gênica/efeitos dos fármacos , Fígado/metabolismo , Células-Tronco/metabolismo , Fator de Crescimento Transformador beta/metabolismo , Albuminas/metabolismo , Animais , Antimetabólitos/administração & dosagem , Antimetabólitos/efeitos adversos , Ductos Biliares/efeitos dos fármacos , Ductos Biliares/metabolismo , Ductos Biliares/patologia , Biomarcadores/metabolismo , Caderinas/metabolismo , Diferenciação Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Deficiência de Colina/etiologia , Deficiência de Colina/metabolismo , Deficiência de Colina/patologia , Desmina/genética , Desmina/metabolismo , Modelos Animais de Doenças , Etionina/administração & dosagem , Etionina/efeitos adversos , Proteínas da Matriz Extracelular/efeitos dos fármacos , Proteínas da Matriz Extracelular/genética , Proteínas da Matriz Extracelular/farmacologia , Proteína Glial Fibrilar Ácida/genética , Proteína Glial Fibrilar Ácida/metabolismo , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Hepatócitos/patologia , Fígado/patologia , Masculino , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Células-Tronco/efeitos dos fármacos , Células-Tronco/ultraestrutura , Fator de Crescimento Transformador beta/farmacologia , alfa-Fetoproteínas/metabolismo
4.
J Pharmacol Exp Ther ; 328(1): 256-62, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18832108

RESUMO

In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice. In the present article, young female mice were fed a choline-deficient, ethionine-supplemented diet. All of the mice developed severe necrotic pancreatitis, and approximately 50% of them died within 4 days. Serum levels of proinflammatory interleukin (IL)-6 significantly increased on day 3 and returned toward the control on day 4 of choline-deficient ethionine-supplemented (CDE) diet treatment. The time course of IL-6 levels paralleled those of plasma amylase and lipase activities. On the other hand, platelet counts significantly decreased on day 3, and the change became more marked on day 4, coinciding with mortality and histological alterations of the pancreas (edema, inflammatory cell infiltration, necrosis). Preceding these changes, plasma levels of 5-hydroxyindoleacetic acid (5-HIAA) increased on feeding a CDE diet to reach a peak on day 3 and returned toward the control on day 4. Risperidone (0.1-3.2 mg/kg twice a day) hardly affected the 5-HIAA levels but dose-dependently attenuated the serum IL-6 levels, plasma amylase/lipase levels, platelet counts, histological alterations, and mortality of diet-induced pancreatitis mice. These results are discussed in relation to the pathogenesis of acute pancreatitis. Thus, we speculate that acinar cell injury triggers local inflammatory reactions and, if coincided with enhanced IL-6 release, leads to a systemic inflammatory response syndrome, which is responsible for the mortality. In addition, it is suggested that diet-induced 5-HT release and 5-HT(2A) receptor activation are involved in this whole process of pancreatitis development. Risperidone may provide a new therapy for the disease.


Assuntos
Anti-Inflamatórios/uso terapêutico , Deficiência de Colina , Pancreatite Necrosante Aguda/induzido quimicamente , Pancreatite Necrosante Aguda/tratamento farmacológico , Pancreatite/diagnóstico , Risperidona/uso terapêutico , Doença Aguda , Amilases/sangue , Animais , Etionina/efeitos adversos , Feminino , Inflamação/fisiopatologia , Inflamação/prevenção & controle , Interleucina-6/sangue , Lipase/sangue , Camundongos , Camundongos Endogâmicos ICR , Pancreatite Necrosante Aguda/sangue , Pancreatite Necrosante Aguda/mortalidade , Análise de Sobrevida
5.
Stem Cell Res ; 1(3): 195-204, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19383400

RESUMO

Liver progenitor (oval) cells have enormous potential in the treatment of patients with liver disease using a cell therapy approach, but their use is limited by their scarcity and the number of donor livers from which they can be derived. Bone marrow may be a suitable source. Previously the derivation of oval cells from bone marrow was examined in rodents using hepatotoxins and partial hepatectomy to create liver damage. These protocols induce oval cell proliferation; however, they do not produce the disease conditions that occur in humans. In this study we have used the choline-deficient, ethionine-supplemented (CDE) diet (which causes fatty liver) and viral hepatitis as models of chronic injury to evaluate the contribution of bone marrow cells to oval cells under conditions that closely mimic human liver disease pathophysiology. Following transplantation of lacZ-transgenic bone marrow cells into congenic mice, liver injury was induced and the movement of bone marrow cells to the liver monitored. Bone marrow-derived oval cells were observed in response to the CDE diet and viral injury but represented a minor fraction (0-1.6%) of the oval cell compartment, regardless of injury severity. In all situations only rare, individual bone marrow-derived oval cells were observed. We hypothesized that the bone marrow cells may replenish oval cells that are expended by protracted liver injury and regeneration; however, experiments involving a subsequent episode of chronic liver injury failed to induce proliferation of the bone marrow-derived oval cells that appeared as a result of the first episode. Bone marrow-derived hepatocytes were also observed in all injury models and controls at a frequency unrelated to that of oval cells. We conclude that during viral-and steatosis-induced liver disease the contribution of bone marrow cells to hepatocytes, either via oval cells or by independent mechanisms, is minimal and that the majority of oval cells responding to this injury are sourced from the liver.


Assuntos
Células da Medula Óssea/fisiologia , Transplante de Medula Óssea , Regeneração Hepática , Animais , Células da Medula Óssea/citologia , Deficiência de Colina , Dieta , Modelos Animais de Doenças , Etionina/administração & dosagem , Etionina/efeitos adversos , Fígado/citologia , Hepatopatias/etiologia , Camundongos , Camundongos Congênicos , Resultado do Tratamento
6.
Acta Radiol ; 38(3): 405-9, 1997 May.
Artigo em Inglês | MEDLINE | ID: mdl-9191431

RESUMO

PURPOSE: To investigate whether liver uptake of the iodinated hepatocyte-specific lipid emulsion FP 736-04 is altered by fatty infiltration of the liver. MATERIAL AND METHODS: Fatty infiltration of the liver was induced in female Sprague-Dawley rats by an intraperitoneal injection of L-ethionine preceded by 15 h of food withdrawal. CT of the liver was performed before and 24 h after the administration of L-ethionine and, in addition at the latter time point, after an i.v. injection of 1.0 ml/kg b.w. of FP 736-04. A control group was subjected to the same CT examination protocol. RESULTS: Intraperitoneal administration of L-ethionine caused liver steatosis, as established by liver triglyceride analysis, leading to a significant decrease in the liver attenuation, from 69.2 +/- 2.4 to 27.8 +/- 12.0 HU. The uptake of FP 736-04 by the fatty liver was significantly reduced, yielding a maximum enhancement of 22.3 +/- 7.9 HU as compared to a value of 32.3 +/- 5.0 HU in the control group. CONCLUSION: Enhancement by FP 736-04 was reduced in the steatotic liver compared with the normal liver. It remains to be established whether this degree of enhancement is sufficient for reliable lesion detection.


Assuntos
Colesterol/farmacocinética , Meios de Contraste , Emulsões Gordurosas Intravenosas/farmacocinética , Fígado Gorduroso/diagnóstico por imagem , Óleo Iodado/farmacocinética , Fígado/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Animais , Antimetabólitos/efeitos adversos , Colesterol/administração & dosagem , Meios de Contraste/administração & dosagem , Meios de Contraste/farmacocinética , Etionina/efeitos adversos , Emulsões Gordurosas Intravenosas/administração & dosagem , Fígado Gorduroso/induzido quimicamente , Feminino , Processamento de Imagem Assistida por Computador , Injeções Intraperitoneais , Injeções Intravenosas , Óleo Iodado/administração & dosagem , Fígado/química , Fígado/citologia , Fígado/metabolismo , Intensificação de Imagem Radiográfica , Ratos , Ratos Sprague-Dawley , Análise de Regressão , Triglicerídeos/análise
7.
Am J Pathol ; 81(1): 87-100, 1975 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1180334

RESUMO

The influence of several factors on the development of acute hemorrhagic pancreatitis (pancreatic necrosis) with fat necrosis in mice fed DL-ethionine with a choline-deficient diet has been investigated. The results showed that: a) the incidence of the induced disease is dependent upon the age and sex of the animals and the dietary level of ethionine; b) 100% of young female mice fed 0.5% ethionine develop acute hemorrhagic pancreatitis and die within 5 days; c) the incidence is only 10 to 20% when 0.5% ethionine is fed with either a choline-supplemented diet or with laboratory chow; and d) development of pancreatic pathology is completely prevented by the inclusion in the diet of 0.5% methionine but not by the inclusion of 0.5% adenine. Possible mechanisms whereby choline deficiency potentiates the pancreatotoxicity of ethionine in mice are discussed.


Assuntos
Adenina/administração & dosagem , Deficiência de Colina/complicações , Dieta , Etionina/administração & dosagem , Metionina/administração & dosagem , Pancreatopatias/etiologia , Doença Aguda , Fatores Etários , Animais , Colina/administração & dosagem , Etionina/efeitos adversos , Feminino , Hemorragia/etiologia , Masculino , Camundongos , Necrose , Pancreatopatias/induzido quimicamente , Pancreatopatias/patologia , Fatores Sexuais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA